Printer Friendly

MAJOR MULTINATIONAL HEART ATTACK STUDY PRESENTATION

 MAJOR MULTINATIONAL HEART ATTACK STUDY PRESENTATION
 WHAT: The preliminary results of the European Myocardial
 Infarction Project, (EMIP), the first study of a sizable
 population of heart attack patients treated within the
 critical two hours after a heart attack, will be announced
 Wednesday, April 15. EMIP is a multi-center,
 multinational study assessing the benefit-risk ratio of
 administering thrombolysis (a clot-busting drug) before a
 heart attack patient reaches a hospital, compared to
 in-hospital administration.
 The study drug is Eminase, the genetically-engineered
 thrombolytic agent that can be administered as an I.V.
 bolus in only five minutes. Eminase is marketed by
 SmithKline Beecham.
 WHERE/
 WHEN: 41st annual meeting of the American College of Cardiology,
 April 11-15, the Dallas Convention Center, Dallas.
 1. ACC-sponsored press conference on EMIP: Wednesday,
 April 15, 1 p.m. CDT, Room N-227 in the Dallas
 Convention Center.
 2. EMIP Symposium: Wednesday, April 15, 4-4:45 p.m.
 CDT, Room E-409 in the Dallas Convention Center.
 WHO: J.P. Boissel, M.D. Alain Leizorovicz, M.D.
 Chief Coordinator of EMIP Lyon, France
 Lyon, France
 Desmond Julian, M.D., F.A.C.C. Peter Maroco, M.D.
 London SmithKline Beecham
 The study results are embargoed until 5 p.m. CDT April 15. Boissel and Leizorovicz can be reached in Dallas this week at the Summit Hotel (214-243-3363), Julian and Maroco at the Loews Anatole (214-748-1200), or through the ACC press room (214-658-7728, -7729 or -7730).
 NOTE: Eminase is a registered trademark.
 CONTACT: Mark Lewis, 202-944-1993, or Ellena Friedman, 202-944-5121, both of Hill and Knowlton for SmithKline Beecham.
 -0- 4/13/92


CO: SmithKline Beecham ST: Texas IN: MTC SU:

DC-SB -- DC025 -- 7898 04/13/92 15:53 EDT
COPYRIGHT 1992 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1992 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Apr 13, 1992
Words:277
Previous Article:REDUCTIONS BY FED, LOWERING OF PRIME RATE WILL HELP FUEL STOCK MARKET-TYPE RALLY FOR HOME MORTGAGES, BROKER SAYS
Next Article:VALUE OF CROSS-BORDER DEALS SOARS 45 PERCENT; INVESTORS TARGET DEVELOPING MARKETS


Related Articles
MAJOR MULTINATIONAL HEART ATTACK STUDY PRESENTATION
FIRST OF TWO RHEOTHRX(R) STUDIES REPORTED: 9,000-PATIENT PHASE III STUDY IN ACUTE MYOCARDIAL INFARCTION PLANNED
CYTRX ANNOUNCES RHEOTHRX(R) INJECTION PHASE III TRIAL INITIATION
NEW TREATMENT MORE THAN HALVES RISK OF HEART ATTACK IN PATIENTS HOSPITALIZED WITH CHEST PAIN
NOVARTIS ANNOUNCES COMPLETION OF ENROLMENT IN ITS VALIANT TRIAL, DESIGNED TO DETERMINE THE EFFECT OF DIOVAN ON LONG-TERM SURVIVAL AFTER HEART ATTACK.
Idun Compounds Reduce Damage and Preserve Function After Heart Attack in Animal Models.
Fondaparinux (Arixtra(R)) to be Studied Worldwide in Over 26,000 Patients Suffering From Acute Coronary Syndrome; MICHELANGELO Study Program - (OASIS...
Phase II study demonstrates promise for Exanta (ximelagatran) in reducing major cardiovascular events following myocardial infarction (MI).
Positive Results from Phase IIa Study Pave Way for Phase IIb Trial of DG051 for the Prevention of Heart Attack.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters